Tyche Wealth Partners LLC Buys 143 Shares of Amgen Inc. (NASDAQ:AMGN)

Tyche Wealth Partners LLC increased its position in Amgen Inc. (NASDAQ:AMGN) by 6.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,280 shares of the medical research company’s stock after acquiring an additional 143 shares during the period. Tyche Wealth Partners LLC’s holdings in Amgen were worth $594,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of AMGN. AMF Tjanstepension AB grew its holdings in Amgen by 16.9% during the third quarter. AMF Tjanstepension AB now owns 120,389 shares of the medical research company’s stock valued at $38,825,000 after purchasing an additional 17,387 shares during the period. Czech National Bank boosted its stake in Amgen by 7.1% during the third quarter. Czech National Bank now owns 109,459 shares of the medical research company’s stock valued at $35,269,000 after buying an additional 7,237 shares during the last quarter. City Center Advisors LLC bought a new position in shares of Amgen during the 3rd quarter valued at approximately $220,000. Atomi Financial Group Inc. lifted its position in Amgen by 4.2% during the third quarter. Atomi Financial Group Inc. now owns 5,388 shares of the medical research company’s stock valued at $1,736,000 after purchasing an additional 217 shares during the last quarter. Finally, City Holding Co. lifted its holdings in shares of Amgen by 0.6% in the 3rd quarter. City Holding Co. now owns 10,719 shares of the medical research company’s stock valued at $3,454,000 after acquiring an additional 67 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on AMGN shares. Bank of America restated an “underperform” rating and issued a $256.00 price target on shares of Amgen in a research report on Tuesday, December 10th. William Blair reiterated an “outperform” rating on shares of Amgen in a report on Tuesday, November 12th. Royal Bank of Canada restated an “outperform” rating and set a $324.00 price objective on shares of Amgen in a report on Friday, January 24th. Wolfe Research initiated coverage on shares of Amgen in a research note on Friday, November 15th. They set a “peer perform” rating for the company. Finally, Sanford C. Bernstein began coverage on shares of Amgen in a research note on Thursday, October 17th. They set an “outperform” rating and a $380.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $314.00.

Amgen Trading Up 6.5 %

Shares of Amgen stock opened at $307.81 on Thursday. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85. The firm has a market capitalization of $165.46 billion, a price-to-earnings ratio of 39.41, a PEG ratio of 2.87 and a beta of 0.56. The firm’s 50 day simple moving average is $271.14 and its two-hundred day simple moving average is $303.52.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 168.35% and a net margin of 13.00%. Analysts predict that Amgen Inc. will post 19.56 EPS for the current year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be given a dividend of $2.38 per share. This is an increase from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a yield of 3.09%. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s dividend payout ratio (DPR) is currently 115.24%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.